Appendix. Survey of Involvement and Participation in Clinical Trials

Physicians are frequently asked to participate in clinical research and are increasingly presented with a wide variety of research projects from which to choose. This questionnaire aims to define the factors which influence hepatologists to participate in clinical research.

I. DEMOGRAPHIC AND PRACTICE INFORMATION

1. Gender Male Female	e 🗆	2. Race/ Ethnicity (Optional)			
3. Age 25-30 years 31-40 years 41- 55 years 56-70 years >70 years		African American Asian Caucasian Hispanic Other (please specify)			
4. Specialty Gastroenterologist Hepatologist Infectious Diseases specialist Internal Medicine specialist Other (please specify)		5. Practice setting Primary Care Center Tertiary Care/ Academic Facility Community Hospital Private Practice Other (please specify)			
6. Current degree MD or equivalent PhD MD/PhD Other (please specify)		7. Years in practice			
8. Please indicate the percentage of time you spend on each of the following professional activities:					
Research-Basic Research-Clinical Research-Academic Clinical- academic Clinical-Private-Practice Industry Other (please specify)	0%	1 - 25% 26 - 50% 51 - 75%	> 75%		

II. EXPERIENCE WITH CLINICAL THERAPEUTIC TRIALS

9. How many clinical trials have you participated in as an investigator during the last <u>12 months</u> ?	none	1 − 4 trials	5 − 10 trials	>10 trials
10. How many clinical trials have you participated in as an investigator during the last <u>5 years</u> ?	none (skip to Q16)	1 – 4 trials	5 − 10 trials	>10 trials

11. Please indicate the type(s) of clinical trials you have participated in as an investigator:						
Drug trials (Human studies) Basic Science Research Non-drug trials (eg. Procedural) Non-drug epidemio logical research Other (please specify)						
12. Please indicate the funding source for clinical trials you have participated in as an investigator:			13. Please indicate in order from 1 to 5 your preference for source of funding for trials (1 = most preferred, 5 = least preferred or N/A):			
Pharmaceutical company Government institutions Non government/ charitable/ philanthropic agencies University/ Hospital funding Other (please specify)			Pharmaceutic Government i Non governm philanthropic University/ H Other (please	nstitutions ent/ charitable agencies ospital fundin	g	_ _ _ _
14. Regardless of whether you currently particithe factors below in influencing your decision to					ate the impo	rtance of
Patient's level of education Patient's race/ethnicity Patient's socioeconomic status Patient's ability to comprehend trial protocols Pressure from patient / patient's family members Concern about losing patient to follow up Anticipated logistical problems (eg travel) Severity of disease Cost incurred by you or your department Cost incurred by the patient Patient's inability to comply or adhere to trial protocol	Extren import	•	Very Important	Somewhat important	Not at all important	Not sure
15. How important are the factors below in influ	uencing	your p	participation	in clinical tri	als?	
Easy access to clinical trials/therapy Level of funding/ equitable compensation for time and effort associated with the trial Relationship or previous experience with the institution conducting the trial Offer from sponsors to fund additional projects/ establish a research fund etc. Recommendation from peers Industry marketing	Extrer impor	tant	Very Important	Somewhat important	Not at all important	Not sure
Intellectual pursuit						

16. Which factors <u>prevent</u> you from participating in clinical trials:					
	Completely prevents me	Is a concern, but doesn't prevent me from participating	Not a concern	Not sure	
Increasing complexity of trials					
Excessive trial costs not covered by the trial sponsor					
Complexity of Institutional Review Board requirements					
Inferior trial medication(s) compared to standard therapy					
Lack of specialized support staff					
Concern about sponsor control of trial decision-making, data, publication, etc					
Too busy with clinical practice commitments					
Ethical considerations					
Difficulty in accessing the appropriate patient population					
Not interested in participating in sponsored clinical research					
17. What is the likelihood of you enrolling the fo	llowing patients	s in clinical therapeut	ic trials?		
		Somewhat	Not at all		
	Very likely	likely	likely	Not sure	
Non English speaking patients					
Patients > 65 yrs					
Unemployed patients					
Patients with reduced numeracy and literacy skills					
Patients with advanced disease					
Uninsured patients					
18. Please indicate your level of interest for part	icipating as an i	investigator in the fol	lowing trials:		
	Very interested	Somewhat interested	Not at all interested	Not sure	
Phase I trials (Initial introduction of an investigational new drug or pilot study to establish a safe dose range)					
Phase II trials (Controlled clinical studies conducted to evaluate the effectiveness of a drug for a particular condition)					
Phase III trials (pre-marketing controlled studies to determine safety, efficacy					
and appropriate dosage for a particular condition) Phase IV trials (Post marketing or open label studies to delineate additional					
information about drug risks, benefits and optimal use) Trials with a study duration = 2 yrs					
Trials with a study duration > 2 yrs					
Trials with a placebo/ non treatment arm Trials involving invasive procedures					

Trials with multiple arms Trials funded by pharmace Trials funded by governm Trials funded by non gove	eutical companies ent agencies				
19. Consider a 45 year old male with Hepatitis C cirrhosis (genotype 1) who is unresponsive to pegylated interferon and ribavirin therapy and requests further treatment. How likely are you to enroll this patient in each of these trials:					
A. A multi-center trial involving long term combination therapy for 5 years with the aim of reversing fibrosis. The trial includes multiple arms with varying doses. The trial is sponsored by a government institution which only funds the cost of the trial drug without reimbursement for additional costs.					
Very likely	Somewhat likely	Not at all likely	Not sure		
B. A 6-month trial involving an oral agent with antiviral effects recommended for non-responders to standard therapy in phase II of clinical trial investigation. The trial includes multiple arms with varying doses. No significant side-effects were reported in phase I of drug evaluation. The trial is sponsored by a pharmaceutical company which funds all trial costs.					
Very likely	Somewhat likely	Not at all likely	Not sure		
C. A 12-month trial of an intravenous agent with anti-fibrotic effects in phase III of development. Minimal side-effects were reported in phase I and II of drug evaluation. The trial includes multiple arms with varying doses and a non-treatment arm. The trial is sponsored by a biotechnology company which funds all trial costs and also provides additional funds for support staff.					
Very likely	Somewhat likely	Not at all likely	Not sure		

Thank you for your participation.